Page 116 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 11. Monitoring parameters in cohorts that did not report information on triggers for intervention in chronological order of starting
enrollment year (continued)

Center, Country Monitoring PSA Gleason # biopsy Imaging Behavioral Additional laboratory Triggers for
[Pubmed ID] schedule score cores /% indication tests interventions
Enrollment cores
years
BCCA, PSA generally every 3-6 mo as needed √ – – – – – NR
Canada 157
[9445192]

NR
Kansas City VA, PSA every 3 mo and a repeat TRUS √ – All biopsies were performed using a standard 12-core – – – NR
US 158 guided prostate biopsy at 1 yr biopsy scheme, but increased number if larger glands
[21172105]

2004-2009
WW = watchful waiting; EM = expectant management; NR = not reported; DT = doubling time; mo = month(s); PAP = prostate acid phosphatase; PSA = prostate specific antigen;
TRUS = Transrectal ultrasound; CT = computerized tomography; PSA = prostate-specific antigen; TNM = tumor-node-metastasis system; US = ultrasound; yr = year(s); BCCA =
British Columbia Cancer Agency
√ = item was used as part of monitoring strategy but explicit criteria were not defined
– = item was not used or not reported as part of monitoring strategy
a The authors reported that five physicians in a nonstandardized fashion followed patients, although a relatively similar pattern of care was provided.

62